A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease
Latest Information Update: 19 Dec 2024
Price :
$35 *
At a glance
- Drugs Etavopivat (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms Hibiscus 2
- Sponsors Novo Nordisk
- 16 Dec 2024 Planned initiation date changed from 16 Dec 2024 to 18 Dec 2024.
- 08 Oct 2024 Planned primary completion date changed from 15 Dec 2025 to 27 Aug 2027.
- 30 Sep 2024 New trial record